JP2008535805A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535805A5
JP2008535805A5 JP2008502205A JP2008502205A JP2008535805A5 JP 2008535805 A5 JP2008535805 A5 JP 2008535805A5 JP 2008502205 A JP2008502205 A JP 2008502205A JP 2008502205 A JP2008502205 A JP 2008502205A JP 2008535805 A5 JP2008535805 A5 JP 2008535805A5
Authority
JP
Japan
Prior art keywords
ser
leu
gly
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008502205A
Other languages
English (en)
Japanese (ja)
Other versions
JP5174653B2 (ja
JP2008535805A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/000438 external-priority patent/WO2006099739A1/en
Publication of JP2008535805A publication Critical patent/JP2008535805A/ja
Publication of JP2008535805A5 publication Critical patent/JP2008535805A5/ja
Application granted granted Critical
Publication of JP5174653B2 publication Critical patent/JP5174653B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008502205A 2005-03-23 2006-03-23 末梢神経毒症状を処置するためのadnfポリペプチドの使用 Expired - Fee Related JP5174653B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66490805P 2005-03-23 2005-03-23
US60/664,908 2005-03-23
PCT/CA2006/000438 WO2006099739A1 (en) 2005-03-23 2006-03-23 Use of adnf polypeptides for treating peripheral neurotoxicity

Publications (3)

Publication Number Publication Date
JP2008535805A JP2008535805A (ja) 2008-09-04
JP2008535805A5 true JP2008535805A5 (cg-RX-API-DMAC7.html) 2009-05-07
JP5174653B2 JP5174653B2 (ja) 2013-04-03

Family

ID=37023352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008502205A Expired - Fee Related JP5174653B2 (ja) 2005-03-23 2006-03-23 末梢神経毒症状を処置するためのadnfポリペプチドの使用

Country Status (6)

Country Link
US (2) US7452867B2 (cg-RX-API-DMAC7.html)
EP (1) EP1885389A4 (cg-RX-API-DMAC7.html)
JP (1) JP5174653B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006227528B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006099739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US7427590B2 (en) * 2001-09-12 2008-09-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurothrophic components of the ADNF I complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
JP5174653B2 (ja) * 2005-03-23 2013-04-03 ラモト アト テルーアビブ ユニバーシティー リミテッド 末梢神経毒症状を処置するためのadnfポリペプチドの使用
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
WO2008084483A1 (en) 2007-01-11 2008-07-17 Ramot At Tel Aviv University Ltd. Novel therapeutics based on tau/microtubule dynamics
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护
US7998928B2 (en) * 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
WO2010033762A1 (en) * 2008-09-18 2010-03-25 Youssef Sari Colivelin as a neuroprotective factor
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2381955A4 (en) * 2008-12-30 2013-01-16 Univ Ramot COMBINATION THERAPIES WITH NAP
EP2467397A1 (en) 2009-08-17 2012-06-27 Ramot at Tel-Aviv University Ltd. Nap alpha-aminoisobutyric acid analog with neuroprotective activity
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
EP2521919B1 (en) 2010-01-06 2015-03-04 Ramot at Tel Aviv University, Ltd. Method for diagnosing and monitoring schizophrenia and tauopathies
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2017130190A1 (en) * 2016-01-28 2017-08-03 Ramot At Tel-Aviv University Ltd. Novel formulation of neuroprotective peptides
EP3245944A1 (en) * 2016-05-20 2017-11-22 Institut Pasteur Olfactory means for the diagnosis of neurological complications of nervous system infection
US11571396B2 (en) 2019-03-23 2023-02-07 Sandra Sermone Ketamine for treatment of ADNP syndrome and sensory processing deficits
EP3979995A4 (en) 2019-06-04 2023-07-26 ADNP Kids Research Foundation Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
WO2022003673A1 (en) 2020-06-30 2022-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Humanin analogs and uses thereof
US20250032580A1 (en) * 2021-03-25 2025-01-30 Ramot At Tel-Aviv University Ltd. Use of adnf polypeptides in therapy
CA3213068A1 (en) 2021-03-25 2022-09-29 Ramot At Tel-Aviv University Ltd. Compositions and articles comprising an adnf polypeptide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740497A (en) 1971-06-29 1973-06-19 G Daniell Artificial line bridge subscriber dial long line equipment tester
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US5198420A (en) * 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US5767240A (en) 1991-04-22 1998-06-16 The United States Of America As Represented By The Department Of Health And Human Services Activity-dependent neurotrophic factor
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
US6613740B1 (en) 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
EP2172478A3 (en) * 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor III (ADNF III)
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649411B2 (en) * 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
DE60010478T2 (de) 1999-08-18 2005-06-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Oral wirksame peptide, die zellschädigung und zelltod verhindern
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US7427598B2 (en) * 2000-05-31 2008-09-23 The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
US20030166544A1 (en) * 2000-09-07 2003-09-04 Clark Abbot F. Use of ADNP for the treatment of glaucomatous optic neuropathy
US7427590B2 (en) * 2001-09-12 2008-09-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurothrophic components of the ADNF I complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
JP5174653B2 (ja) * 2005-03-23 2013-04-03 ラモト アト テルーアビブ ユニバーシティー リミテッド 末梢神経毒症状を処置するためのadnfポリペプチドの使用
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护

Similar Documents

Publication Publication Date Title
US11851481B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
AU2017295708A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
US20140322250A1 (en) Peptides for the Treatment of Multiple Sclerosis and Related Diseases
BRPI0809234A2 (pt) Peptídeos de proteína associada a receptor (rap) cíclico
JP2013533890A5 (cg-RX-API-DMAC7.html)
JP2008518026A5 (cg-RX-API-DMAC7.html)
JP2022508952A (ja) ジルコプランによる神経疾患治療
CN104582796A (zh) 治疗阿尔茨海默病的组合物和方法
JP2025120320A (ja) Vipr2アンタゴニストペプチド
WO2013082045A1 (en) Netrin loop peptide mimetics and uses thereof
CN102574904B (zh) 赋予了经粘膜吸收性的胃动素样肽化合物
WO2014052766A1 (en) Hepatocyte growth factor mimics as therapeutic agents
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
JP4744443B2 (ja) 毒素中和性ペプチドのスクリーニング方法とstx2阻害性ペプチド並びにベロ毒素中和剤
EP1602931A1 (en) SR-A antagonists
CN1361865A (zh) 起催化作用的抗因子ⅷ同种抗体
JP2007515157A5 (cg-RX-API-DMAC7.html)
US20140336127A1 (en) Stabilized Peptide Helices For Inhibiting Dimerization Of Chemokine C Motif Receptor 2 (CCR2)
WO2022093684A1 (en) Compositions and methods of treating inflammatory lung diseases
TW476650B (en) Use of a cytokine regulatory agent to treat rheumatoid arthritis
WO2026094984A1 (ja) 抗ウイルス活性を有するペプチドの塩形
KR20250028388A (ko) 펩타이드 억제제 및 이의 용도
JP2009502797A5 (cg-RX-API-DMAC7.html)
JP6578546B2 (ja) Lt阻害4価ペプチドおよびetec感染症治療薬
JP2619268B2 (ja) 新規なペプチド硫酸エステル誘導体